Oncology billing services for medical oncology, hematology, and radiation oncology practices
Oncology billing services BillingAndCoding provides
Insurance eligibility and benefit verification
Coverage is confirmed before each treatment cycle rather than once at intake, because oncology benefits change mid-treatment when a patient meets a deductible, switches plans at open enrollment, or moves onto Medicare. Verification covers active coverage, medical versus pharmacy benefit routing for each drug, remaining deductible and coinsurance, and any specialty pharmacy or white bagging mandate written into the plan. Under original Medicare, a patient owes 20 percent coinsurance on Part B drugs with no annual out-of-pocket cap, so the cost estimate given before an infusion has to be built on verified numbers.
Prior authorization for drugs, imaging, and radiation
Commercial and Medicare Advantage plans require prior authorization for most physician-administered cancer drugs, for PET imaging billed under CPT codes 78811 through 78816, and for radiation courses such as IMRT. Requests are submitted with the regimen, dosing, and staging pulled from the treatment plan, and each approval is logged with its authorization number, approved units, and expiration date. A regimen change triggers a new request the same day, since a swapped drug or an escalated dose administered under an old authorization comes back as a denial.
Oncology coding: CPT, ICD-10-CM, and HCPCS
Chemotherapy administration coding follows the CPT initial-service hierarchy: chemotherapy codes (96401 through 96549) rank above therapeutic infusions (96365 through 96379), which rank above hydration (96360 and 96361), and only one initial service is reported per encounter per vascular access site. A three-hour infusion of a single agent is coded 96413 for the first hour plus two units of 96415, and a second sequential drug adds 96417. Diagnosis sequencing follows the ICD-10-CM guideline that Z51.11 is listed first when the encounter is solely for chemotherapy administration, with the malignancy code from C00 through C96 reported second. Radiation oncology claims cover planning, delivery, and the treatment management code 77427, which is billed once per five fractions.
Chemotherapy drug billing, units, and waste
Every drug claim is checked against the HCPCS code descriptor before submission. J9271 is defined as 1 mg of pembrolizumab, so a 200 mg dose bills as 200 units, while a code defined in 10 mg increments requires the dose divided by ten. For dates of service on or after July 1, 2023, Medicare requires either the JW modifier reporting the discarded amount from a single-dose vial or the JZ modifier attesting to zero waste, and since October 2023 claims missing both are returned as unprocessable. Units are also screened against CMS Medically Unlikely Edits, which cap billable units per code per day. Biosimilars bill under their own codes, such as Q5107 for bevacizumab-awwb, rather than the reference product’s J code.
Clean claim submission
Denials are worked within 72 hours of posting, sorted by remark code and dollar value so high-cost drug denials move first. Medical necessity denials are appealed with the treatment plan, pathology, and the supporting citation from the NCCN Drugs and Biologics Compendium, which Medicare recognizes for covering off-label uses in anticancer regimens. Medicare redetermination requests are filed inside the 120-day window, and commercial appeals follow each contract’s deadline, which can run as short as 90 days. Timely filing is tracked from the date of service: Medicare allows 12 months, and many commercial contracts allow 90 or 180 days.
Payment posting and underpayment recovery
Electronic remittances post within one business day of receipt, and every drug payment is reconciled against the quarterly Medicare ASP fee schedule or the contracted commercial rate. A payer reimbursing 2 percent under contract on a $10,000 infusion claim shorts the practice $200 on that one encounter, so variances are flagged at posting and pursued instead of written off. Patient statements go out after insurance finalizes and itemize drug and administration charges on separate lines.
Why oncology billing needs a specialty team
Drug dollars dominate the oncology revenue cycle in a way no other specialty matches. Under buy-and-bill, the practice purchases pembrolizumab, nivolumab, or a biosimilar from a distributor before treatment and then waits on reimbursement, so one denied immunotherapy claim can leave more than $10,000 of paid-for inventory unreimbursed. A denied office visit in most other specialties risks a payment in the low hundreds.
CMS built an entire payment model around this cost structure. The Enhancing Oncology Model began July 1, 2023, added a second cohort on July 1, 2025, and runs through June 30, 2030. Participating practices are accountable for total Medicare spending across six-month episodes triggered by chemotherapy for seven cancer types, and they bill $110 per beneficiary per month ($140 for dually eligible patients) for enhanced services. Whether a practice participates in the model or reports under MIPS, the underlying claims data has to reconcile cleanly against CMS benchmarks, and that starts with accurate coding and posting.
Get an oncology billing assessment
An assessment starts with 90 days of remittance data and returns a written summary of denial rate by reason code, days in accounts receivable, and drug payment variance against the Medicare ASP fee schedule. Contact BillingAndCoding at info@billingandcoding.us or +1 (734) 418 2537, or request a free consultation through the appointment form.